Use of convalescent plasma therapy in SARS patients in Hong Kong

Cheng, Yi; Wong, R.C.P.; Soo, Yannie; Wong, Wing Sze; Lee, C. K.; Ng, Margaret H.L.; Chan, Paul K.S.; Wong, Kwok Chuen; Leung, Chi Bon; Cheng, Gregory

doi:10.1007/s10096-004-1271-9

Cited by 929 publications

(1,063 citation statements)

References 10 publications

Supporting

Mentioning

986

Contrasting

Unclassified

Order By: Relevance

“…Passive antibodies have been used to prevent or treat such diseases as rabies, measles, hepatitis B, cytomegalovirus, and respiratory syncytial virus (6), and convalescent human plasma may have efficacy in the treatment of severe acute respiratory syndrome (7,8 modern plasmapheresis systems in many hospitals and blood collection centers currently produce large volumes of plasma for treating coagulopathies and other conditions (9, 10). The same infrastructure, personnel, and regulatory framework could produce convalescent plasma for the treatment of H5N1 influenza.…”

mentioning

confidence: 99%

Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

et al. 2006

View full text Add to dashboard Cite

Background: Studies from the Spanish influenza era reported that transfusion of influenza-convalescent human blood products reduced mortality in patients with influenza complicated by pneumonia. Treatments for H5N1 influenza are unsatisfactory, and convalescent human plasma containing H5N1 antibodies could be an effective therapy during outbreaks and pandemics.Purpose: To determine whether transfusion with influenza-convalescent human blood products reduced the risk for death in patients with Spanish influenza pneumonia.Data Sources: Manual search of English-language journals from 1918 to 1925. Citations from retrieved studies were also searched.Study Selection: Published English-language studies that had at least 10 patients in the treatment group, used convalescent blood products to treat Spanish influenza pneumonia in a hospital setting, and reported on a control or comparison group. Data Extraction:Two investigators independently extracted data on study characteristics, outcomes, adverse events, and quality. Data Synthesis: Eight relevant studies involving 1703 patients were found. Treated patients, who were often selected because of more severe illness, were compared with untreated controls with influenza pneumonia in the same hospital or ward. The overall crude case-fatality rate was 16% (54 of 336) among treated patients and 37% (452 of 1219) among controls. The range of absolute risk differences in mortality between the treatment and control groups was 8% to 26% (pooled risk difference, 21% [95% CI, 15% to 27%]). The overall crude case-fatality rate was 19% (28 of 148) among patients who received early treatment (after Ͻ4 days of pneumonia complications) and 59% (49 of 83) among patients who received late treatment (after Ն4 days of pneumonia complications). The range of absolute risk differences in mortality between the early treatment group and the late treatment group was 26% to 50% (pooled risk difference, 41% [CI, 29% to 54%]). Adverse effects included chill reactions and possible exacerbations of symptoms in a few patients.Limitations: Studies were few and had many methodologic limitations. No study was a blinded, randomized, or placebo-controlled trial. Some pertinent studies may have been missed. Conclusions:Patients with Spanish influenza pneumonia who received influenza-convalescent human blood products may have experienced a clinically important reduction in the risk for death. Convalescent human H5N1 plasma could be an effective, timely, and widely available treatment that should be studied in clinical trials.Ann Intern Med. 2006;145:599-609. www.annals.org For author affiliations, see end of text. The world is bracing for a potential H5N1 influenza pandemic. During the Spanish influenza pandemic, an estimated 30% of the world's population became ill and 50 million people died (1). An H5N1 influenza pandemic could be equally or more severe. Unfortunately, effective vaccines will be difficult to produce before a novel human pandemic strain emerges and will take substantial time to manufactur...

show abstract

mentioning

confidence: 99%

Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Possible interventions that need to be investigated include convalescent plasma from recovered cases. The premise of this approach is based on some evidence from the treatment of cases with severe acute respiratory virus infection caused by SARS-CoV [52], highly pathogenic avian influenza A (H5N1) [53] and most recently by the 2009 pandemic influenza virus [54]. This will require that affected countries, WHO and the WHO Collaborating Centres work together to establish an international novel coronavirus convalescent plasma centre that can strengthen the Region's public health preparedness against this infection.…”

Section: Clinical Carementioning

confidence: 99%

Novel coronavirus infection in the Eastern Mediterranean Region: time to act

Malik¹,

Mafi²,

Mahjour³

et al. 2013

East Mediterr Health J

View full text Add to dashboard Cite

The Eastern Mediterranean Region of World Health Organization has been an emerging focus for global health after the discovery of a novel coronavirus infection in some countries in the Region. The Region has already witnessed a number of emerging zoonoses with epidemic potential. In view of this new virus, there is now an urgent need for strong public health vigilance and monitoring of the evolution of the virus in the Region. The situation will challenge and test the national health authorities' resilience and ability to respond in a timely manner. This review summarizes the evidence related to the emergence in the Region of new epidemic diseases of predominantly zoonotic origin and the challenges posed by the discovery of the novel coronavirus infection, and outlines recommendations for the countries for early detection, prevention and control of public health threats from this novel coronavirus infection.

show abstract

“…Die erfolgreiche Anwendung von Rekonvaleszentenplasma bei lebensbedrohenden Infektionen wurde ebenfalls in "case studies" beschrieben, insbesondere bei Influenzavirus-oder SARS-Coronavirus-Infektionen [2][3][4][5].…”

unclassified

“…In der neueren Literatur finden sich Berichte, dass bei mehreren Infektionskrankheiten, vor allem im asiatischen Raum, positive Erfahrungen mit RKP als Therapieoption bei schweren, ansonsten therapierefraktären, Verläufen gesammelt wurden. Insbesondere wurde bei dem Ausbruch von Ebola Vollblut [7] und in einem Fall RKP [8] sowiebei SARS RKP in kleineren, nicht kontrollierten, offenen Studien [4,5] In Abhängigkeit von der vorliegenden Rechtslage ist zu prüfen, ob eine Än-derungsanzeige bei der zuständigen Behörde nach § 20 AMG wegen eines Abweichens von den Spendereignungs-und Rückstellungskriterien erforderlich ist. …”

unclassified

Stellungnahme zur Gewinnung und Nutzung von Rekonvaleszentenplasma (RKP) als Therapieoption bei Ausbrüchen schwerer Infektionen

2015

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Use of convalescent plasma therapy in SARS patients in Hong Kong

Cited by 929 publications

References 10 publications

Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

Novel coronavirus infection in the Eastern Mediterranean Region: time to act

Stellungnahme zur Gewinnung und Nutzung von Rekonvaleszentenplasma (RKP) als Therapieoption bei Ausbrüchen schwerer Infektionen

Contact Info

Product

Resources

About